An overview of human leptospirosis vaccine design and future perspectives. (1st February 2020)

• Record Type: Journal Article
• Authors: Felix, Carolina R.; Siedler, Bianca S.; Barbosa, Liana N.; Timm, Gabriana R.; McFadden, Johnjoe; McBride, Alan J. A.
• Is Part Of: Expert opinion on drug discovery. Volume 15:Number 2(2020)
• Page Start: 179
• Page End: 188
• Publication Date: 2020-02-01
• Subjects: Leptospira -- universal vaccine -- reverse vaccinology -- structural vaccinology; 615.1
• DOI: 10.1080/17460441.2020.1694508
• Languages: English
• ISSNs: 1746-0441

Abstract

ABSTRACT: Introduction : It's been 20 years since the first report of a recombinant vaccine that protected against leptospirosis. Since then, numerous recombinant vaccines have been evaluated; however, no recombinant vaccine candidate has advanced to clinical trials. With the ever-increasing burden of leptospirosis, there is an urgent need for a universal vaccine against leptospirosis. Areas covered : This review covers the most promising vaccine candidates that induced significant, reproducible, protection and how advances in the field of bioinformatics has led to the discovery of hundreds of novel protein targets. The authors also discuss the most recent findings regarding the innate immune response and host–pathogen interactions and their impact on the discovery of novel vaccine candidates. In addition, the authors have identified what they believe are the most challenging problems for the discovery and development of a universal vaccine and their potential solutions. Expert opinion : A universal vaccine for leptospirosis will likely only be achieved using a recombinant vaccine as the bacterins are of limited use due to the lack of a cross-protective immune response. Although there are hundreds of novel targets, due to the lack of immune correlates and the need for more research into the basic microbiology of Leptospira spp., a universal vaccine is 10–15 years away.